A Phase 1 interventional study of Pimecrolimus cream and Betamethasone dipropionate cream in Atopic Dermatitis, sponsored by LEO Pharma. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-24.
Sponsored by LEO Pharma · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing pimecrolimus in Dermatitis, Atopic — none open to participants now, none under way, none of them phase 3. pimecrolimus · Dermatitis, Atopic.
Among the 27 studies testing pimecrolimus in Dermatitis, Atopic, this one is the 20th largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2015, is one of 2 in phase 1, and was the 24th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →None of the 27 studies testing pimecrolimus in Dermatitis, Atopic is open now. The open studies under Dermatitis, Atopic, anywhere →
pimecrolimus: first FDA approval 2001 (ELIDEL). What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 113 across the 24 interventional studies. Of the 27 that completed or were terminated, 4 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 27 have an industry lead sponsor. The 10 most frequent:
LEO Pharma is the lead sponsor of 225 studies on the registry; 5 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 24 (75%) have results posted.
36 studies in Dermatitis, Atopic by LEO Pharma: 1 open now, 1 under way, 1 of them phase 3. Of 34 finished, 15 (44%) have results posted.
Among the 36 studies in Dermatitis, Atopic by LEO Pharma, this one is the 26th largest by enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2015, is one of 14 in phase 1, and was the 13th registered.
LEO Pharma’s Dermatitis, Atopic studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 27 studies testing pimecrolimus in Dermatitis, Atopic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among LEO Pharma’s 36 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
An Explorative Clinical Trial to Evaluate an Intra Patient Comparison Design of Topical Agents in Adults with Mild to Moderate Atopic Dermatitis.
Multi-center, prospective, randomized, vehicle-controlled, investigator-blinded, stable lesion design.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pimecrolimus 1% cream once daily for 14 days
Drug: Pimecrolimus cream
Betamethasone dipropionate 0.05% cream once daily for 14 days
Drug: Betamethasone dipropionate cream
Clobetasol propionate 0.05% cream once daily for 14 days
Drug: Clobetasol propionate cream
Glaxal Base cream vehicle once daily for 14 days
Drug: Glaxal Base cream vehicle
Also known as: Elidel
Also known as: Diprosone, Diprolene
Also known as: Dermovate
Also known as: emollient cream
Total Sign Score (TSS) change
TSS change at end of treatment in relation to baseline
Time frame: 14 days
Plan to share: No
The record gives a start of Feb 2015, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pimecrolimus · Betamethasone dipropionate · Clobetasol